资料显示，三力士股份有限公司位于浙江省绍兴市柯桥区柯岩街道凤凰创新园，成立日期2002年11月11 日，上市日期2008年4月25日，公司主营业务涉及生产并销售各类橡胶V带、同步带等产品。主营业务 收入构成为：橡胶V带72.73%，其他27.27%。 三力士今年以来股价涨3.03%，近5个交易日跌0.67%，近20日跌3.28%，近60日跌2.86%。 分红方面，三力士A股上市后累计派现4.63亿元。近三年，累计派现8972.71万元。 责任编辑：小浪快报 12月18日，三力士盘中上涨2.08%，截至10:23，报4.42元/股，成交2837.33万元，换手率0.80%，总市值 39.87亿元。 三力士所属申万行业为：基础化工-橡胶-其他橡胶制品。所属概念板块包括：低价、小盘、体育产业、 工业大麻、储能等。 资金流向方面，主力资金净流入37.60万元，特大单买入0.00元，占比0.00%，卖出207.12万元，占比 7.30%；大单买入694.00万元，占比24.46%，卖出449.29万元，占比15.83%。 截至12月10日，三力士股东户数5.00万，较上期减少0.18%；人均流通股16140股，较上期增 ...

格隆汇12月18日丨顺灏股份(002565.SZ)在投资者互动平台表示，为了抓住海外工业大麻快速发展的机 遇，公司在美国设立了子公司 E10 Labs和 S10 Labs，通过全面科学的市场研究为生产研发提供依据， 给公司工业大麻业务发展提供具有前瞻性的市场信息支持,力求逐步满足国际市场对工业大麻提取物以 及终端产品的需求。其中，E10 Labs 获准在当地开展加工制造相关业务并在美国以及全球其他合法国 家和地区开展销售的合法资格，已经推出加热不燃烧系列产品；S10 Labs主要为工业大麻雾化器硬件提 供商。 ...

Core Viewpoint - The company is strategically positioning itself to capitalize on the growing opportunities in the industrial hemp market in the United States by establishing subsidiaries and conducting market research [1] Group 1: Company Initiatives - The company has set up two subsidiaries in the U.S., E10 Labs and S10 Labs, to leverage the rapid development of the industrial hemp sector [1] - E10 Labs has been granted the legal qualification to engage in processing and manufacturing activities locally, as well as to sell products in the U.S. and other legally compliant countries [1] - The company has launched a series of heat-not-burn products through E10 Labs, indicating its commitment to innovation in the industrial hemp space [1] Group 2: Market Research and Development - The company emphasizes the importance of comprehensive scientific market research to support production and R&D efforts, aiming to provide forward-looking market information [1] - The subsidiaries are focused on meeting the international market demand for industrial hemp extracts and end products [1] - S10 Labs primarily serves as a provider of hardware for industrial hemp vaporizers, showcasing the company's diversified approach within the industry [1]

工业大麻股盘前再度上涨，CbdMD涨近14%，Canopy Growth涨超7%，Tilray Brands涨近2%。 消息人士称，美国总统特朗普预计最早将于本周签署行政命令，放宽对大麻的分类管制，并首次在联邦 层面承认大麻的医疗用途。据悉，行政命令预计将指示美国缉毒局或司法部就重新分类管制颁布最终规 定，将大麻由一级管制物质降至第三级。同时，行政命令可能还包括指示国会通过法案，让合法的大麻 企业能够获得主要银行及金融机构的服务。消息人士称，行政命令亦有可能指示医疗保险及医疗补助服 务中心，允许在医疗保险报销大麻二酚(CBD)产品。(格隆汇) ...

工业大麻股盘前大涨，Tilray Brands涨超25%，Canopy Growth涨超21%，极光大麻、SNDL涨超14%。 消息面上，美媒援引知情人士消息称，美国政府预计将推动联邦层面大幅放宽对大麻的管制，将大麻及 其衍生物的监管力度降至与部分常见处方止痛药及其他药物相同的水平。美国总统特朗普10日在白宫椭 圆形办公室与美国共和党籍众议院议长迈克·约翰逊通话时讨论了这一计划。(格隆汇) ...

一位白宫官员表示，关于重新分类的最终决定尚未作出。重新分类将使购买和销售大麻变得更加容易， 大麻企业一直在游说政府推动改革，而重新分类的决定可能会减轻税负和银行服务方面的障碍。 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 格隆汇12月12日｜A股市场工业大麻概念股走强，其中，顺灏股份涨停，福安药业、蓝晓科技、金鹰股 份涨超4%，诚益通、永吉股份、晨光生物涨超3%。 有消息称特朗普预计将指示政府推进将大麻重新归类为危害较低的药物，这一举措可能成为数十年来美 国大麻政策最重大的转变之一。 知情人士称，特朗普已经与大麻行业高管、卫生与公众服务部部长小罗伯特·F·肯尼迪，以及医疗保险 与医疗补助服务中心(CMS)负责人Mehmet Oz讨论了这一想法。 ...

金融工程 证 券 研 究 报 告 市场情绪监控周报（20251201-20251205） 本周热度变化最大行业为通信、食品饮料 本周市场估值跟踪 本周宽基和行业估值： 沪深 300、中证 500、中证 1000 的滚动 5 年历史分位数分别为 85%、95%、 94%。 申万一级行业中，从 2015 年开始回溯，当前估值处于历史分位数 80%以上的 一级行业有：电力设备、轻工制造、银行、电子、商贸零售、钢铁、计算机、 国防军工、煤炭、环保、建筑材料、医药生物；位于估值历史 20%以下的有食 品饮料、综合、非银金融； 申万二级行业中，从 2015 年开始回溯，目前处于历史分位数 80%以上的二级 行业有航天装备、软件开发、国有大型银行、冶钢原料、生物制品、风电设备、 化学制药、环保设备、服装家纺、普钢、旅游及景区、橡胶、航空机场、专业 连锁、装修建材、半导体、商用车、照明设备、互联网电商、数字媒体、化学 纤维、汽车服务、多元金融、工程机械。 本周市场热度跟踪 本周宽基热度变化方面：热度变化率最大的为"其他"，相比上周提高 1.54%， 最小的为中证 1000，相比上周降低 1.98%。 本周申万行业热度变化方面 ...

Core Viewpoint - Tonghua Jinma's stock price has shown significant volatility, with a year-to-date increase of 76.31%, but a recent decline of 3.72% over the last five trading days [1] Group 1: Stock Performance - As of November 26, Tonghua Jinma's stock price was 27.68 CNY per share, with a market capitalization of 26.753 billion CNY [1] - The stock has experienced a trading volume of 73.0787 million CNY, with a turnover rate of 0.28% [1] - The company has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) twice this year, with the latest appearance on September 11, where it recorded a net buy of 142 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million CNY, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.9635 million CNY, an increase of 4.35% [2] - The company's main business revenue composition includes biopharmaceuticals (59.27%), traditional Chinese medicine (40.56%), raw materials (0.10%), and others (0.07%) [1] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tonghua Jinma was 38,200, a decrease of 3.20% from the previous period [2] - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with varying changes in their holdings [3]

Group 1 - The core viewpoint of the news is that Aoyang Health has shown fluctuations in stock performance, with a year-to-date increase of 35.14% but a recent decline in the last five trading days by 5.58% [1] - As of November 25, Aoyang Health's stock price was 4.23 CNY per share, with a market capitalization of 3.239 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 3.5156 million CNY, with significant buying and selling activities noted [1] Group 2 - For the period from January to September 2025, Aoyang Health reported operating revenue of 1.36 billion CNY, a year-on-year decrease of 9.39%, while the net profit attributable to shareholders was 40.1137 million CNY, reflecting a year-on-year increase of 3.71% [2] - The company has a total of 58,300 shareholders as of September 30, which is a decrease of 10.91% from the previous period, while the average circulating shares per person increased by 12.24% to 13,121 shares [2] - Aoyang Health has cumulatively distributed dividends of 26.1 million CNY since its A-share listing, with no dividends distributed in the last three years [3]

Core Viewpoint - Hengfeng Paper's stock price has experienced fluctuations, with a year-to-date increase of 22.77% but a recent decline in the last five and twenty trading days [1][2]. Company Overview - Hengfeng Paper, established on March 6, 1994, and listed on April 19, 2001, is located in Mudanjiang, Heilongjiang Province. The company specializes in the production and sale of specialty papers, including cigarette paper, filter rod paper, and aluminum foil lining paper [1]. - The revenue composition of Hengfeng Paper includes 65.48% from tobacco industrial paper, 15.50% from other paper types, 11.75% from mechanical gloss paper, 6.08% from thin printing paper, and 1.19% from other sources [1]. Financial Performance - As of September 30, 2025, Hengfeng Paper reported a revenue of 2.039 billion yuan, reflecting a year-on-year growth of 6.29%. The net profit attributable to shareholders was 148 million yuan, marking a significant increase of 34.76% compared to the previous year [2]. - The company has distributed a total of 680 million yuan in dividends since its A-share listing, with 115 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Hengfeng Paper was 14,600, a decrease of 12.06% from the previous period. The average circulating shares per person increased by 13.71% to 20,445 shares [2]. - Notable new institutional shareholders include the Jiangyin State-owned Enterprise Reform Flexible Allocation Mixed A Fund, which holds 5.6999 million shares, and the招商量化精选股票发起式A Fund, holding 4.3094 million shares [3].